在全球，大概每10个育龄女性中就有1个饱受子宫内膜异位症的折磨——这是一种影响约1.9亿女性的高 发疾病，90%的患者经历着间断性的盆腔疼痛，26%甚至面临不孕的阴影。 然而，当Organon近日宣布其"明星候选药物"OG-6219在二期临床试验中宣告失败时，这个本应充满希 望的领域再次被蒙上阴霾。 OG-6219曾被寄予厚望，被Organon视为"重塑痛经治疗标准"的突破，但它的失败不仅让Organon的女性 健康创新管线陷入危机，更揭示了子宫内膜异位症药物研发的深层困境： 一个影响数亿人的市场，为何新药寥寥无几？痛经药物的春天究竟何时才能到来？ 01 需求巨大，供给稀缺 痛经，尤其严重的痛经，很可能是一种病——子宫内膜异位症。子宫内膜异位症远不止痛经那么简单， 不仅可以侵袭周围组织和其他器官，导致复杂的症状，还容易在治疗后反复发作，直到绝经后才能缓 解，给患者带来无尽的痛苦折磨。 理论上，子宫内膜异位症拥有巨大的治疗需求与商业空间，但现实却是新药稀缺，研发缓慢。 更早前，拜耳也曾布局这一领域，其靶向孕激素/催乳素（ER/PR）药物Visanne于2010年首次在欧洲获 批，用于治疗子宫内膜异位症引发的疼痛 ...

Core Viewpoint - India has submitted its "best offer" for trade negotiations to the U.S., with the fate of a temporary agreement now resting with President Trump [2] Group 1: Trade Negotiations - India has set clear red lines in the negotiations, including restrictions on U.S. exports of genetically modified crops and opening its dairy and automotive sectors to the U.S. [2][3] - The Indian government, led by Prime Minister Modi, has adopted a cautious stance in negotiations due to increasing pressure to protect its politically sensitive agricultural sector [2] - The U.S. is seeking access to India's genetically modified crop market, while India has proposed limited imports of genetically modified animal feed, which the U.S. has rejected [3] Group 2: Political Context - The Indian National Congress party expresses skepticism about Modi's ability to resist U.S. demands, predicting he will yield before the tariff deadline [4] - The agricultural sector is crucial for millions of Indians, and farmer groups warn against excessive concessions to the U.S. that could jeopardize their livelihoods [3][4] - The Indian government currently prohibits the cultivation of genetically modified food crops, despite some potential benefits for yield improvement [3]

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum were held in Beijing, focusing on the future development of the pharmaceutical industry through insights, ecosystem building, and resource integration [1][3] - The list of "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue for 2024" was released, with Sichuan Good Doctor Panzhihua Pharmaceutical Co., Ltd. making the list for the 14th consecutive year, showcasing its sustained comprehensive strength [1][3] - Good Doctor Pharmaceutical Group Co., Ltd. received the "2025 China Pharmaceutical Industry Growth Potential Enterprise Map" award, reflecting industry recognition of its future development potential [1][3] Group 2 - The annual conference has been a significant event since its inception in 1959, witnessing the growth and technological innovation of China's pharmaceutical industry [3] - The conference aims to promote the integration of cutting-edge technological innovation concepts with resources from top pharmaceutical companies, driving innovation and transformation in the industry [3] - The global biopharmaceutical industry is undergoing profound changes, with advancements in AI, synthetic biology, gene editing, and cell therapy accelerating China's pharmaceutical industry's shift towards innovation and high-end development [3] Group 3 - In 2024, Good Doctor Group will invest over 800 million yuan to establish a digital intelligent factory for the production of biological raw materials and large-scale traditional Chinese medicine, enhancing production efficiency and product quality [4] - The construction of the second phase of the digital intelligent factory not only improves the production capacity and level of traditional Chinese medicine but also serves as a model for digital projects, promoting high-quality development in the pharmaceutical production sector in Xichang and Liangshan [4]

Investment Rating - The industry rating is "Recommended" [3] Core Insights - The report emphasizes the importance of the pig farming sector amidst stricter environmental regulations and rising pork prices, suggesting a focus on investment opportunities in this area [2][12] - The report highlights the expected increase in autumn grain production, driven by favorable soil conditions and government initiatives aimed at enhancing crop yields [1][11] Summary by Sections Planting Industry Chain - The current main flood season poses risks for agricultural disasters, with regional droughts and floods expected [1] - The Ministry of Agriculture aims to achieve a grain production target of approximately 1.4 trillion jin, focusing on key crops and regions [1][11] - The commercialization of genetically modified crops is anticipated to accelerate, enhancing self-sufficiency in key varieties [1][11] - Recommended stocks include Beidahuang and Suqian Agricultural Development in the planting sector, and leading seed companies like Longping High-Tech and Denge Seed Industry [1][11] Pig Farming - The average price of external three-way cross pigs is 15.17 yuan/kg, with a week-on-week increase of 4.97% [2][12] - The number of breeding sows is projected to reach 40.42 million by May 2025, with a slight increase from previous periods [2][12] - The report suggests focusing on companies with significant cost improvements and high future output elasticity, including Dekang Agriculture, Jingji Zhino, Muyuan Foods, and Wen's Foodstuffs [2][12] Key Agricultural Product Data Tracking - Corn: The average price is 2435.68 yuan/ton, with a week-on-week increase of 0.37% [24] - Wheat: The average price is 2450.52 yuan/ton, with a week-on-week increase of 0.18% [27] - Rice: The average price is 2892 yuan/ton, remaining stable [32] - Soybeans: The average price is 3926.32 yuan/ton, with a week-on-week decrease of 0.30% [39] - Cotton: The average price is 15130 yuan/ton, with a week-on-week increase of 1.54% [44] Feed and Vitamin Prices - The average price of pig feed is 2.69 yuan/kg, with a week-on-week increase of 0.75% [50] - Vitamin E averages 69.90 yuan/kg, with a week-on-week decrease of 5.16% [57]

Group 1 - The core viewpoint of the articles highlights the rapid growth and innovation in Beijing's pharmaceutical and healthcare industry, with the city becoming the first in China to surpass a trillion yuan in industry scale [2][3]. - During the 14th Five-Year Plan period, Beijing has launched 12 innovative drugs and approved 54 national innovative medical devices, accounting for nearly one-fourth of the national total [1][3]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, with 40 developed by Chinese companies, showcasing the strength of local innovation [2][3]. Group 2 - Changping District has signed agreements for 14 major projects, focusing on providing comprehensive services for enterprise development in the pharmaceutical sector [4][5]. - The district has established 57 industrial service platforms, facilitating seamless transitions from incubation to research and development, and clinical trials [4]. - The pharmaceutical health industry in Changping has seen an average annual revenue growth of 9.3% over the past three years, forming a billion-yuan industry cluster [4][5].

编辑丨王多鱼 排版丨水成文 在动物基因组中，被称为 增强子 （ enhancer ） 的调控性 DNA 元件控制着特定细胞类型中基因表达的精确时空模式。然而，增强子在细胞核内的空间组织以调 控靶基因的方式，目前仍知之甚少。 2025 年 7 月 2 日 ，北京大学生物医学前沿创新中心 （ BIOPIC ） /昌平实验室 谢晓亮 院士团队在 Nature Genetics 期刊发表了题为 ： Single-cell Micro-C profiles 3D genome structures at high resolution and characterizes multi-enhancer hubs 的研究论文。 研究团队开发了 单细胞 Micro-C （scMicro-C） 技术，这种是基 于微球菌核酸酶 （ Micrococcal nuclease ） 的 3D 基因组图谱技术，能够以 高分辨率描绘 3D 基因组结构，并表征了 多增强子中心 （ multi-enhancer hub ） ，即多个增强子与基因启动子相关联，形成空间簇。 此外，该研究还观察到，在单细胞 3D 基因组结构中，具有 PES 的基因 ...

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum opened, focusing on the layout of pharmaceutical research and the transformation of original achievements, with 14 major pharmaceutical health industry projects signed in Changping District [1] - Major projects include investments from companies such as Mindray Medical, Diyi Group, Yourui Bio, and others, as well as innovative collaborations with institutions like Shantou University and the National Research Institute of High-Performance Medical Devices [1][2] - The Beijing Future Pharmaceutical Industry Chain Research Institute was unveiled, aiming to support key technology collaboration and promote international development of the pharmaceutical industry [1] Group 2 - A joint initiative was launched among Tsinghua University, Peking University, China Agricultural University, and Beijing University of Chemical Technology to drive breakthroughs in biomedicine and synthetic biology, enhancing China's position in the global pharmaceutical value chain [2] - The "Support Measures for the Development of the Pharmaceutical Health Industry in the Changping Group of the China (Beijing) Free Trade Pilot Zone" were announced, focusing on cross-border R&D cooperation and aligning with international standards [2] - Changping District has established a complete industrial chain from basic research to terminal medical services, with an average annual growth rate of 9.3% in pharmaceutical health industry revenue over the past three years, projected to reach 104 billion yuan in 2024, a year-on-year increase of 14.3% [2][3] Group 3 - The district has seen continuous innovation, with four key technologies selected as major scientific achievements for the 2025 Zhongguancun Forum, and 27 cell and gene therapy pipelines entering clinical stages, accounting for 5% of the national total [3] - The Zhongguancun synthetic biology manufacturing industry cluster has attracted 121 innovative enterprises, and the "Future City" health industry has formed a 10 billion yuan cluster [3] - Changping District aims to enhance the ecosystem of industrial elements and improve service quality, striving to make the Life Science Park a globally competitive hub for the pharmaceutical health industry [3]

Group 1 - The core idea of the news is the establishment of a student presentation team by Shandong Normal University to deepen the education of party history and promote patriotism among youth through a series of practical activities in various cities [1] - The first activity took place at the Laiwu Battle Memorial Hall, where students from Shandong Normal University and Jinan University participated in learning and social practice [1][6] - The activities included a visit to the memorial, sharing sessions, and a themed presentation on the history of the Communist Party of China [1][9] Group 2 - The Laiwu Battle Memorial Hall is the only comprehensive venue in Shandong Province that reflects the anti-Japanese war efforts in the central Shandong region, showcasing the significant Laiwu battle led by Chen Yi and Cu Yu in February 1947 [2] - The memorial features valuable historical artifacts and documents that provide a detailed account of the battle, emphasizing the hardships faced by the military and civilians in Shandong [2][8] - A panoramic display at the memorial uses modern technology to recreate the battle scenes, enhancing the immersive experience for visitors [5] Group 3 - Following the visit, a presentation titled "Opening a New Era, the Red Boat Sails" was delivered, highlighting the significance of the first National Congress of the Communist Party of China and the essence of the Red Boat spirit [9] - The presentation emphasized the importance of innovation, perseverance, and dedication to the public as core values derived from the party's founding spirit [9] - A plaque unveiling ceremony for the establishment of a social practice base between Shandong Normal University and the Laiwu Battle Memorial Hall was held, aiming to provide students with opportunities to learn about the history of the anti-Japanese war [12][14] Group 4 - The collaboration between the two universities promotes inter-school exchanges and helps innovate talent cultivation models [14] - The establishment of the practice base is intended to transform red resources into educational advantages, allowing students to experience revolutionary spirit and cultivate patriotism [12][14] - The Laiwu visit marks a successful start to the themed practice "Red Path to Seek Historical Traces, Youth Voices Together" [14]

行 业 定 期 报 告 生猪养殖：供应缩减，猪价大幅上涨。（1）本周猪价宽幅上行。近期 集团场阶段性降重任务完成后出栏节奏放缓，供应缩量推动猪价持续上涨， 7 月 4 日全国生猪均价为 15.37 元/公斤，周环比+0.71 元/公斤。6 月 21-30 日二次育肥销量占比 0.93%，较 6 月 11-20 日的 0.91%增长 0.02pct。随着 猪价持续走高，二次育肥进场成本增加，补栏端已转为观望，而部分养殖 户接受当前高价，出栏意向有所增强。（2）本周屠企宰量下跌。高温限制 猪肉消费，白条走货难度增强，加之现阶段猪价高位，限制屠企分割入库 意愿，本周样本屠企宰量继续下滑。6 月 28 日-7 月 4 日涌益样本屠企日均 宰杀量为 13.80 万头，周环比-3.83%。（3）本周生猪出栏均重反弹。集团 场 6 月中上旬出栏节奏加快，出栏体重下降明显，随后月末、月初出栏节 奏放缓，短期主动降重速度放慢，而散户端大猪出栏积极性提升带动出栏 均重上涨。7 月 3 日当周生猪出栏均重 128.64kg（周环比+0.50kg），其中 集团场均重124.59kg（周环比-0.25kg）、散户均重140.73kg（ ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 基于 免疫检查点抑制剂 （ICI） 的免疫检查点阻断疗法，已彻底改变了多种实体瘤的治疗方式，但其仍面 临着耐药性的问题。此外，在 晚期和复发性卵巢癌中，免疫检查点阻断疗法效果不佳，患者对 单药 PD- 1/PD-L1 抑制剂的应答率仅在 5%-15% 之间，因此，仍需探索新的策略的来改善患者的临床解决。 2025 年 7 月 2 日， 德克 萨斯 大学MD安德森癌症中心 Amir Jazaeri 教授、 王凌华 教授、 张如刚 教授 团队合作 （ 王凌华团队的 戴一博 、 党明浩 等 作为共同第一作者） ， 在 Nature 期刊发表了题为： PPP2R1A mutations portend improved survival after cancer immunotherapy 的研究论文。 研究团队在临床试验中观察到，携带 PPP2R1A 基因突变的 卵巢透明细胞癌 患者在接受抗 PD-1/PD-L1 单抗 与抗 CTLA4 单抗 联合免疫治疗后，生存期显著优于 PPP2R1A 野生型的患者。研究团队进一步发 现， PPP2R1A 基因 突变可提高肿瘤对于免疫疗法 ...